Takuji Okusaka Selected Research

Biomarkers (Surrogate Marker)

6/2022	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
8/2021	The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions.
1/2019	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
3/2018	Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma.
5/2017	Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
1/2017	Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
1/2016	Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
11/2015	Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
10/2013	Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
2/2012	Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takuji Okusaka Research Topics

Disease

87	Neoplasms (Cancer) 12/2022 - 01/2002
86	Pancreatic Neoplasms (Pancreatic Cancer) 08/2022 - 01/2002
82	Hepatocellular Carcinoma (Hepatoma) 09/2022 - 01/2002
38	Biliary Tract Neoplasms (Biliary Tract Cancer) 06/2022 - 12/2002
16	Adenocarcinoma 10/2020 - 01/2002
14	Neutropenia 10/2020 - 04/2004
14	Thrombocytopenia (Thrombopenia) 01/2018 - 02/2005
13	Disease Progression 02/2021 - 03/2007
10	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2021 - 02/2011
10	Neoplasm Metastasis (Metastasis) 01/2016 - 04/2004
9	Anorexia 01/2019 - 06/2006
8	Hypertension (High Blood Pressure) 06/2020 - 03/2011
7	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2022 - 08/2010
7	Ascites 03/2022 - 12/2007
7	Cholangiocarcinoma 11/2020 - 11/2007
7	Leukopenia 10/2020 - 02/2005
6	Fibrosis (Cirrhosis) 06/2022 - 12/2010
6	Carcinoma (Carcinomatosis) 11/2020 - 08/2005
6	Exanthema (Rash) 01/2019 - 02/2011
5	Stomach Neoplasms (Stomach Cancer) 06/2022 - 04/2014
5	Gallbladder Neoplasms (Gallbladder Cancer) 08/2021 - 11/2007
5	Liver Neoplasms (Liver Cancer) 10/2020 - 05/2012
5	Anemia 10/2020 - 02/2011
5	Liver Diseases (Liver Disease) 02/2020 - 01/2006
5	Nausea 10/2018 - 06/2006
5	Fatigue 01/2017 - 04/2008
5	Infections 12/2016 - 09/2002
5	Carcinogenesis 01/2016 - 05/2012
4	Liver Cirrhosis (Hepatic Cirrhosis) 06/2022 - 02/2002
4	Body Weight (Weight, Body) 01/2021 - 01/2005
4	Neuroendocrine Carcinoma 01/2020 - 04/2010
3	Pathologic Constriction (Stenosis) 12/2022 - 09/2020
3	Hepatitis C 06/2022 - 01/2015
3	Hemorrhage 07/2019 - 01/2004
3	Stomatitis 01/2019 - 02/2011
3	Hepatitis 01/2019 - 09/2012
3	Diarrhea 12/2016 - 02/2011
3	Drug-Related Side Effects and Adverse Reactions 10/2014 - 04/2005

Drug/Important Bio-Agent (IBA)

80	Gemcitabine FDA Link 01/2022 - 12/2002
32	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2003
28	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 03/2010
22	Pharmaceutical PreparationsIBA 07/2022 - 12/2002
19	Fluorouracil (Carac)FDA LinkGeneric 10/2018 - 02/2002
16	Biomarkers (Surrogate Marker)IBA 06/2022 - 11/2005
14	Proteins (Proteins, Gene)FDA Link 03/2022 - 01/2011
12	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019 - 11/2002
11	RamucirumabIBA 06/2020 - 07/2015
8	lenvatinibIBA 09/2022 - 03/2016
8	Alanine Transaminase (SGPT)IBA 06/2017 - 02/2005
7	folfirinoxIBA 08/2022 - 10/2014
7	PlatinumIBA 10/2020 - 04/2004
7	alpha-Fetoproteins (alpha-Fetoprotein)IBA 06/2020 - 01/2006
6	Peptides (Polypeptides)IBA 01/2021 - 12/2009
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 02/2011
6	BilirubinIBA 10/2019 - 04/2004
6	ProteomeIBA 02/2012 - 11/2005
6	TegafurIBA 03/2011 - 01/2002
5	Antineoplastic Agents (Antineoplastics)IBA 07/2022 - 05/2015
5	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2011
5	Everolimus FDA Link 11/2021 - 02/2011
5	Protein Subunit VaccinesIBA 01/2021 - 12/2010
5	Monoclonal AntibodiesIBA 01/2021 - 05/2014
5	Epirubicin (Ellence)FDA LinkGeneric 02/2018 - 01/2003
5	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 01/2007
5	EnzymesIBA 11/2015 - 09/2004
5	UracilIBA 03/2011 - 01/2002
4	Biological ProductsIBA 12/2020 - 09/2002
4	Irinotecan (Camptosar)FDA LinkGeneric 10/2018 - 03/2007
4	miriplatinIBA 02/2018 - 04/2004
4	C-Reactive ProteinIBA 01/2016 - 01/2009
4	Ethiodized Oil (Ethiodol)FDA Link 01/2014 - 01/2002
4	S 1 (combination)IBA 01/2013 - 12/2010
3	Serum AlbuminIBA 06/2022 - 11/2002
3	GlypicansIBA 01/2021 - 04/2014
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 03/2011
3	130-nm albumin-bound paclitaxelIBA 01/2021 - 10/2018
3	Axitinib (AG 013736)IBA 01/2021 - 03/2011
3	LigandsIBA 01/2021 - 01/2011
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2020 - 01/2018
3	Sunitinib (Sutent)FDA Link 06/2019 - 10/2013
3	Fetal Proteins (Fetoprotein)IBA 01/2019 - 01/2015
3	Immune Checkpoint InhibitorsIBA 01/2019 - 01/2018
3	Streptozocin (Streptozotocin)FDA Link 10/2018 - 07/2015
3	Mitoxantrone (Novantrone)FDA LinkGeneric 06/2017 - 02/2005
3	Hepatitis B Surface Antigens (HBsAg)FDA Link 12/2016 - 09/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2015 - 03/2011
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 07/2015 - 02/2011
3	(2E,4E,6E,10E)- 3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acidIBA 06/2015 - 06/2011
3	Transaminases (Aminotransferases)IBA 02/2015 - 01/2005
3	orantinib (SU6668)IBA 10/2014 - 02/2011

Therapy/Procedure

98	Drug Therapy (Chemotherapy) 06/2022 - 01/2002
75	Therapeutics 09/2022 - 12/2002
13	Radiotherapy 01/2021 - 06/2003
11	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 01/2005
9	Chemoradiotherapy 02/2021 - 01/2004
8	Stents 12/2022 - 10/2014
3	Self Expandable Metallic Stents 12/2022 - 01/2021
3	Choledochostomy 04/2022 - 01/2021
3	Adjuvant Chemotherapy 10/2018 - 09/2012
3	Immunotherapy 01/2018 - 12/2009